Asia Pacific Dermal Fillers Market size crossed USD 1 billion in 2021 and is projected to showcase around 11.3% growth rate between 2022 and 2028.
Dermal fillers, also known as injectable implants, wrinkle fillers, or soft tissue fillers are used for smother and fuller appearance of the face. These are the materials designed to be injected into the skin to add volume and fullness. They are also known as injectable implants, wrinkle fillers or soft tissue fillers. These fillers are approved for producing smoother and fuller appearance in the face, including nasolabial folds, chin, and lips. Increasing demand and awareness regarding cosmetic procedures in emerging nations is expected to boost the market growth.
Get more details on this report - Request Free Sample PDF
Awareness regarding anti-aging cosmetic procedures has increased significantly coupled with expanding geriatric population base in the region is anticipated to positively impact the Asia Pacific dermal fillers market growth. According to the UNFPA, the number of people aged 60 years and over in Asia Pacific is projected to reach 1.3 billion by 2050. Dermal fillers help the elderly individual’s aesthetics by restoring lost volume and uplifting sagging skin, therefore, driving the consumer preference and product demand. Additionally, dehydration and wrinkling of the skin is increasing among elderly population. Thus, hyaluronic acid is commonly used for aesthetic purposes for providing superior wrinkle-erasing abilities.
Asia Pacific Market, By Type
The biodegradable dermal fillers segment generated more than USD 1 billion revenue in 2021, attributed to minimal complications associated with the use of these fillers. Moreover, semi-permanent fillers offered at competitive and affordable prices will further assist in increasing the adoption rate of these product segment. Additionally, biodegradable filler materials such as hyaluronic acid and calcium hydroxyapatite (CaHA) are safe and lasts for lesser timespan allowing consumer to switch back to their original look.
Asia Pacific Dermal Fillers Market, By Material Type
The hyaluronic acid (HA) dermal fillers segment will grow at 11% CAGR during the forecast period, owing to its usage across broad range of cosmetic applications. As HA is naturally occurring substance in the body, it has minimal negative effect on human body when used. HA fillers are mostly used for deeper lines and wrinkle treatment as they offer long-term sustainability owing to their thicker consistency.
Asia Pacific Market, By Application
The facial line correction segment accounted for 40% Asia Pacific dermal fillers market share in 2021, due to growing demand of dermal fillers among elderly population to diminish signs of aging coupled with increasing awareness and consciousness regarding facial aesthetics. Additionally, increasing popularity of such procedures increases its adoption rate will further accelerate the market demand.
Asia Pacific Market, By End-use
The dermatology clinics segment revenue was over USD 500 million in 2021, credited to increasing number of cosmetic procedures in dermatology clinics owing to the availability of advanced techniques and enhanced patient care. Also, expanding number of dermatology clinics, offering customized services to patients will positively influence the industry outlook.
Asia Pacific Market, By Country
Japan dermal fillers market size will witness 10.5% CAGR through 2028, on account of sophisticated healthcare infrastructure and increasing awareness about aesthetic procedures in the country. Increasing spending ability of the population will further augment the industry demand. Moreover, rising adoption of advanced technologies and growing awareness regarding beauty enhancement techniques will collectively drive the market value.
Competitive Industry Landscape
Prominent participants operating across the Asia Pacific dermal fillers market include Merz Pharma, Galderma, Croma Pharma GmbH, Huons Global Co., Ltd. (Humedix), Prollenium Medical Technologies, Shanghai Bioha Technology Co., Ltd, Sinclair Pharma (Huadong Medicine Co., Ltd.), Suneva Medical, Inc, Cytophil, Inc, Teoxane Laboratories, Zhejiang Jingjia Medical Technology Co., Ltd, AbbVie Inc. (Allergan plc), BioScience GmBH.